熱門資訊> 正文
ORIC Pharmaceuticals GAAP每股收益为-0.45美元
2024-08-13 04:54
- ORIC Pharmaceuticals press release (NASDAQ:ORIC): Q2 GAAP EPS of -$0.45.
- Spectral AI GAAP EPS of -$0.16 misses by $0.01, revenue of $7.5M beats by $1.12M
More on ORIC Pharmaceuticals
- ORIC Pharmaceuticals Stock: Too Early To Justify This Valuation
- ORIC Pharma: ORIC-114 Advancement To Phase 1b Expansion Study Could Yield Value
- ORIC collaborates with Bayer, J&J on prostate cancer study
- Seeking Alpha’s Quant Rating on ORIC Pharmaceuticals
- Historical earnings data for ORIC Pharmaceuticals
風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。